|
|
||||||||
Ann Thorac Surg 1999;68:2256-2257
© 1999 The Society of Thoracic Surgeons
a Department of Anesthesiology, Duke University Medical Center, Box 3094, Durham, NC 27710, USA
e-mail: slaug003@mc.duke.edu
Invited commentary
In somewhat less than a decade, prophylactic administration of antifibrinolytic drugs has achieved such widespread acceptance that in some institutions, my own included, antifibrinolytic infusions during cardiac operations requiring cardiopulmonary bypass have become a "standard of care." This remarkable feat has occurred to a great extent in response to aprotinin. Pharmaceutical-sponsored efficacy trials of aprotinin have demonstrated significant reductions in blood loss and transfusion requirements. Unfortunately, as Casati and colleagues point out in their discussion, the costs associated with aprotinin therapy have led investigators to seek alternative, less costly antifibrinolytics for perioperative applications. In fact,
Related Article
-aminocaproic acid in primary cardiac surgery
Ann. Thorac. Surg. 1999 68: 2252-2256.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |